Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

21.20USD
4:00pm EDT
Change (% chg)

$0.07 (+0.33%)
Prev Close
$21.13
Open
$21.10
Day's High
$21.39
Day's Low
$20.88
Volume
802,887
Avg. Vol
1,284,156
52-wk High
$23.42
52-wk Low
$3.88

EXEL.OQ

Chart for EXEL.OQ

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 1.94
Market Cap(Mil.): $6,146.01
Shares Outstanding(Mil.): 290.87
Dividend: --
Yield (%): --

Financials

  EXEL.OQ Industry Sector
P/E (TTM): -- 49.14 30.32
EPS (TTM): -0.30 -- --
ROI: -23.14 -2.23 13.10
ROE: -- 5.00 14.24

BRIEF-Exelixis further reduces indebtedness by repaying Silicon Valley Bank term loan

* Exelixis further reduces indebtedness by repaying silicon valley bank term loan

Mar 29 2017

BRIEF-Exelixis' cabozantinib granted orphan drug designation

* Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma

Mar 06 2017

BRIEF-Exelixis announces clinical trial collaboration with Roche

* Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors

Feb 27 2017

BRIEF-Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab

* Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors

Feb 17 2017

BRIEF-Exelixis and Takeda enter into exclusive licensing agreement

* Exelixis and Takeda enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in Japan

Jan 30 2017

BRIEF-Genentech withdraws counterclaim against Exelixis in JAMS arbitration

* Update on dispute between Exelixis and Genentech, a member of the Roche group

Jan 09 2017

BRIEF-Exelixis announces Q3 and YTD 2016 financial results

* Exelixis announces third quarter and year to date 2016 financial results and provides corporate update

Nov 03 2016

BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib

* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib

Oct 11 2016

BRIEF-Ipsen and Exelixis announce positive results from Phase 2 CABOSUN trial of cabozantinib

* Ipsen and its partner Exelixis announce positive results from Phase 2 CABOSUN Trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

Oct 10 2016

BRIEF-Exelixis announces Phase 1 trial results for Cabozantinib in combination with Nivolumab in advanced Genitourinary tumors

* Says findings will be presented during a poster discussion session on October 9

Oct 07 2016

More From Around the Web

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 4,927.00 -27.50
Pfizer Inc. (PFE.N) $34.35 +0.02
ArQule, Inc. (ARQL.OQ) $1.07 -0.02
Bayer AG (BAYGn.DE) €106.80 -0.10
Bayer AG (BAYE.F) -- --
Bristol-Myers Squibb Co (BMY.N) $55.36 -0.59
Bristol-Myers Squibb Co (BMYMP.PK) $1,001.97 --
Eli Lilly and Co (LLY.N) $84.76 +0.32
Sanofi SA (SASY.PA) €84.24 -0.27
Amgen, Inc. (AMGN.OQ) $164.38 +1.32

Earnings vs. Estimates